Abstract
Abstract
Background
Viral hepatitis is a global public health problem affecting millions of people worldwide, causing thousands of deaths due to acute and persistent infection, cirrhosis, and liver cancer. Providing updated serologic data can improve both surveillance and disease control programs. This study is aimed to determine the seroprevalence of markers for viral hepatitis (A, B, C, D and E) and the epidemiology of such infections in the general population of southern Iran’s Hormozgan province.
Methods
Between 2016 and 2017, a total of 562 individuals with ages ranging from 1 to 86 years, who visited governmental public laboratories for routine check-ups, were tested for the presence of serological markers to hepatitis virus types A to E using enzyme-linked immunosorbent assays.
Results
The overall anti-hepatitis A virus (HAV) antibody seroprevalence was 93.2% (524/562). The prevalence of anti-hepatitis E virus (HEV) antibodies was 15.8% (89/562) among which 1.6% (9/562) of the seropositive individuals also had evidence of recent exposure to the virus (IgM positivity). Two and a half percent (14/562) were positive for hepatitis B surface (HBs) antigen, whereas 11.6% (65/562) tested positive for anti-hepatitis B core (HBc) antibodies. Among anti-HBc positive patients, 11% (7/65) had HBs Ag and 5% (3/65) were positive for anti-hepatitis D virus (HDV) antibodies. The prevalence of anti-hepatitis C virus (HCV) antibodies was 0.7% (4/562). The seroprevalence of anti-HAV, HEV IgG, anti-HBc antibodies, and HBs Ag increased with age.
Conclusion
The present study confirms a high seroprevalence of HAV infection among the examined population and reveals high levels of endemicity for HEV in the region. Planned vaccination policies against HAV should be considered in all parts of Iran. In addition, improvements on public sanitation and hygiene management of drinking water sources for the studied area are recommended.
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Martin A, Lemon SM. Hepatitis a virus: from discovery to vaccines. Hepatology. 2006;43(S1):S164–72.
2. Thuener J. Hepatitis A and B Infections. Prim Care. 2017;44(4):621–9.
3. Shin E-C, Jeong S-HJ. Natural history, clinical manifestations, and pathogenesis of hepatitis a. Cold Spring Harb Perspect Med. 2018;8(9):a031708.
4. Asaei S, Ziyaeyan M, Moeini M, Jamalidoust M, Behzadi MA. Seroprevalence of hepatitis a and E virus infections among healthy population in Shiraz, Southern Iran. Jundishapur J Microbiol. 2015;8(7):e19311.
5. Safiabadi M, Rezaee-Zavareh MS, Alavian SM. Estimation of hepatitis a virus infection prevalence among eastern Mediterranean and middle eastern countries: a systematic review and pooled analysis. Hepat Mon. 2017;17(2):e44695.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献